Long-term follow-up of methotrexate and cytarabine in adult patients with Langerhans cell histiocytosis.
Langerhans cell histiocytosis
long‐term follow‐up
methotrexate and cytarabine
systemic therapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
20 Oct 2024
20 Oct 2024
Historique:
received:
29
07
2024
accepted:
02
10
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
aheadofprint
Résumé
The optimal treatment strategy for adult Langerhans cell histiocytosis (LCH) remains unclear. Our previous study demonstrated the remarkable efficacy of combined methotrexate and cytarabine (Ara-C) [MA] therapy in patients newly diagnosed with LCH, with a median follow-up of 2 years. The present article reports long-term follow-up data spanning a median of 78 months (6.5 years) from a single-arm, single-centre, prospective phase 2 clinical trial (NCT02389400) conducted between January 2014 and December 2020. Ninety-five adults with newly diagnosed LCH exhibiting multisystem disease or multifocal single-system involvement underwent MA therapy every 35 days for six cycles. Methotrexate (1 g/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82370179
Organisme : National Key R&D Program of China
ID : 2022YFC2304605
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-B-046
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Rodriguez‐Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. https://doi.org/10.1182/blood.2019000934
Tazi A, Lorillon G, Haroche J, Neel A, Dominique S, Aouba A, et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis. 2017;12(1):95. https://doi.org/10.1186/s13023‐017‐0651‐z
Cantu MA, Lupo PJ, Bilgi M, Hicks MJ, Allen CE, McClain KL. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257. https://doi.org/10.1371/journal.pone.0043257
Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022;139(17):2601–2621. https://doi.org/10.1182/blood.2021014343
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(11):1277–1303. https://doi.org/10.6004/jnccn.2021.0053
Goyal G, Abeykoon JP, Hu M, Young JR, Shah MV, Bennani NN, et al. Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis. Am J Hematol. 2021;96(5):E146. https://doi.org/10.1002/ajh.26119
Chang L, Lang M, Lin H, Cai H, Duan MH, Zhou DB, et al. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia. 2024;38(4):803–809. https://doi.org/10.1038/s41375‐024‐02174‐1
Makras P, Yavropoulou MP, Chatziioannou SN, Anastasilakis AD, Georgakopoulou D, Tsoli M, et al. Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: a prospective clinical trial. Am J Hematol. 2023;98(7):E168–E171. https://doi.org/10.1002/ajh.26936
Allen CE, Beverley PCL, Collin M, Diamond EL, Egeler RM, Ginhoux F, et al. The coming of age of Langerhans cell histiocytosis. Nat Immunol. 2020;21(1):1–7. https://doi.org/10.1038/s41590‐019‐0558‐z
Chen J, Zhao AL, Duan MH, Cai H, Gao XM, Liu T, et al. Diverse kinase alterations and myeloid‐associated mutations in adult histiocytosis. Leukemia. 2022;36(2):573–576. https://doi.org/10.1038/s41375‐021‐01439‐3
Lin H, Cao XX. Current state of targeted therapy in adult Langerhans cell histiocytosis and Erdheim‐Chester disease. Target Oncol. 2024;19:691–703. https://doi.org/10.1007/s11523‐024‐01080‐x
Cao XX, Li J, Zhao AL, He TH, Gao XM, Cai HC, et al. Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study. Am J Hematol. 2020;95(9):E235–E238. https://doi.org/10.1002/ajh.25864
Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high‐dose methotrexate. Oncologist. 2016;21(12):1471–1482. https://doi.org/10.1634/theoncologist.2015‐0164
Cao XX, Duan MH, Zhao AL, Cai H, Chen J, Gao XM, et al. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. Am J Hematol. 2022;97(2):203–208. https://doi.org/10.1002/ajh.26412
Goyal G, Acosta‐Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, et al. Long‐term outcomes among adults with Langerhans cell histiocytosis. Blood Adv. 2023;7:6568–6578. https://doi.org/10.1182/bloodadvances.2023010706
Goyal G, Parikh R, Richman J, Abeykoon JP, Morlote D, Go RS, et al. Spectrum of second primary malignancies and cause‐specific mortality in pediatric and adult Langerhans cell histiocytosis. Leuk Res. 2023;126:107032. https://doi.org/10.1016/j.leukres.2023.107032
Acosta‐Medina AA, Kemps PG, Zondag TCE, Abeykoon JP, Forma‐Borst J, Steenwijk EC, et al. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood. 2023;142(18):1570–1575. https://doi.org/10.1182/blood.2023021212
Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high‐risk Langerhans cell histiocytosis and increased resistance to first‐line therapy. J Clin Oncol. 2016;34(25):3023–3030. https://doi.org/10.1200/jco.2015.65.9508
Lei J, Wang W, Lin D, Zhu C, Jia W, Weng W, et al. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi‐center observational study. J Cancer Res Clin Oncol. 2024;150(1):12. https://doi.org/10.1007/s00432‐023‐05551‐y